Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study

NCT04134390 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Old Age; Debility
Renal Carcinoma Metastatic

Interventions

DRUG: Cabozantinib

Sponsor

Spanish Oncology Genito-Urinary Group

Collaborators

[object Object]